GBA Holding GmbH

The GBA Group is expanding its international laboratory network and is represented in Switzerland for the first time with the addition of laboratory service provider NIUTEC AG (NIUTEC). With this acquisition, the GBA Group is once again strengthening its positioning in the growing market for the qualification of medical devices. Furthermore, the partnership with NIUTEC creates a strong basis for further development in the important local Swiss market for environmental analysis. NIUTEC AG, which was founded in 2000 as a spin-off of the Sulzer Group, currently employs around 50 people. The focus in the field of medical devices is on purity and biocompatibility testing, material testing and other technical services. In the environmental sector, NIUTEC offers specialized services for soil, waste, water, gas and air analyses. “We are very pleased to be shaping our future together with the NIUTEC team!”, says Steffen Walter, CEO GBA Group, ”We are relying both on the strengthening of NIUTEC through our European competence network and on the local entrepreneurial dynamism of our new colleagues in order to offer our customers the best possible range of services.” “By partnering with the GBA Group, we are joining forces to develop innovative solutions for future challenges. This will help us to react even faster to market changes, expand our customer base and keep the company on course for growth. This partnership is an important step in our strategic development,” explain Agi Mosberger and Daniel Zurbrügg, co-owners of NIUTEC. Please direct any queries to: GBA GROUP Sabine Nest presse@gba-group.de

The GBA Group is continuing its international growth strategy by acquiring the Dutch company BAAT Holding B.V. (BAAT Medical), a leading provider of design and development services for medical devices. With this strategic acquisition, the GBA Group strengthens its position in the European medical device market, among other things by expanding its service portfolio in the development phase from the product idea to product development and successful market launch. BAAT Medical was founded in the Netherlands in 1999 and is based in Hengelo. Baat Medical offers its international customers a wide range of services in the development, implementation and maintenance of medical devices based on international quality standards such as ISO 13485 and the legal framework of the MDR (EU) and FDA (USA). Steffen Walter, CEO GBA Group, welcomes the new colleagues: “With BAAT Medical, we have found a partner that perfectly complements our existing service portfolio in the field of medical devices. In addition to testing and consulting, we can now also offer development services from a single source within the GBA Group and support customers in all phases of the product life cycle with solutions and regulatory expertise.” “It was crucial for BAAT Medical to find a partner that not only brings a complementary network in the medical field and a physical presence outside Europe, but also respects our identity and way of working. GBA Group meets all these criteria and shares our vision of growth opportunities, making the partnership an ideal fit,” explains Gert Nijenbanning, General Manager BAAT Medical. Please direct any queries to: GBA GROUP Sabine Nest presse@gba-group.de

GBA Group is expanding its range of toxicology services for customers in the chemical, medical device and pharmaceutical industries with the acquisition of ICCR-Roßdorf GmbH (ICCR-Roßdorf). This acquisition underlines GBA Group's ambition to position itself broadly as an international life science service provider through targeted portfolio expansions and investment in leading CROs. Today's ICCR-Roßdorf GmbH (Institute for Competence Contract Research - Roßdorf) was founded in 1986 and has its headquarters with almost 100 employees in Roßdorf near Darmstadt. The focus of ICCR-Rossdorf is the investigation of the genotoxic potential of pharmaceuticals, agrochemicals, cosmetics and chemicals. For customers in the field of medical devices, the service portfolio is supplemented with modified protocols for the investigation of the effects of extracts. Dr. Sabine Gorynia, Executive Vice President Pharma & Medical Devices, GBA Group, underlines the synergies resulting from the merger: "With more than 30 years of experience, one of the world's leading Gentox providers enriches the portfolio and business network of GBA Group. We are pleased to further strengthen our growth in the preclinical area together with our colleagues from ICCR-Roßdorf and to be able to offer our national and international customers another important component in an even broader service portfolio." Dr. Markus Schulz, Managing Director of ICCR: "The constructive and open discussion in the run-up to the transaction showed that the closer cooperation between GBA Group and ICCR-Roßdorf offers great opportunities. This applies both to the broad use of the solutions and expertise we have developed in the toxicology field within the GBA Group and to joint projects in the development of innovative assays in new areas of application." Please direct any queries to: GBA GROUP Sabine Nest presse@gba-group.de